Amundi's €620 million buys ten years of ICG shelf space

Amundi said on September 17 that it had completed the acquisition of a 9.9% economic stake in ICG for approximately €620 million, the last step in a partnership the two firms announced in November 2025. The filing discloses a stake; the ten-year distribution agreement underneath it is what will move both firms' numbers. Under that agreement Amundi becomes ICG's exclusive global distributor in the wealth channel for the asset manager's evergreen and certain other products, and ICG becomes Amundi's exclusive provider of those products to Amundi's distribution business.

Amundi's own disclosure says how much it expects the arrangement to count: from the third quarter, its assets under management, net flows and financial results will reflect the contribution tied to the 9.9% interest, which pulls a share of ICG's earnings into the flow numbers Amundi reports every quarter. The benefit runs both ways: ICG gets a distribution arm reaching wealth clients globally without building one, and Amundi gets product it cannot manufacture quickly. Chief executive Valérie Baudson called the partnership a significant step in the development of Amundi's private markets offering and a platform for products tailored to investors' evolving needs, while ICG chief executive and chief investment officer Benoît Durteste pointed to the "commercial benefits" the two firms are already finding and to opportunities to deepen the collaboration.

This is Amundi's second private-markets transaction in a month. In August, as this publication reported, Amundi backed Victory Capital's $7 billion deal for First Eagle as a 27 percent owner and lead distributor, a transaction we read as a private-credit bet: the combined $571 billion manager was paying for a CLO distribution engine, and the $280 million synergy target was the proof of price. The roles have flipped: then Amundi was the distributor blessing another firm's acquisition; now it is the buyer, and what it bought, beyond a 9.9% interest that secures representation without control, is a ten-year claim on the products ICG manufactures.

The reciprocal structure is where the deal gets interesting, and where the risk sits. Amundi has committed its wealth distribution to ICG's evergreen range for a decade, occupying shelf space that might otherwise have carried a competitor's semi-liquid fund. ICG has committed supply exclusively to Amundi in those categories, which narrows a strategy that could have been sold through several platforms to a single channel. Both sides gave up optionality, and both presumably priced it into the €620 million — a figure that implies an equity value of roughly €6.3 billion for ICG.

Whether that price was right turns on flows rather than on the sticker. The stake entitles Amundi to a share of ICG's earnings; the distribution agreement pays it a share of the fees on assets Amundi's own reach helps raise, and that second stream scales with distribution rather than with ICG's investment performance. Because Amundi has said the contribution will show up in reported net flows, investors get a clean test of the thesis within a few quarters.

What the structure does not say is how the two pieces are priced against each other. If 9.9% of ICG is worth €620 million on its own, Amundi collected the ten-year distribution agreement for nothing; if the stake went for a premium, the exclusivity is embedded in the price and ICG has effectively been prepaid for product it has not yet delivered. The second reading is the likelier one for a deal a year in the making, and it shifts the burden squarely onto the pipeline: the joint products have to raise enough through Amundi's wealth channel to justify whatever premium the stake carried.

The first product out of the joint pipeline, expected in the coming weeks, is a private equity secondaries fund. Durteste described it as an evergreen vehicle giving access to ICG's LP Secondaries strategy, and the choice of secondaries as the opening move fits the channel it is built for. Secondaries vehicles buy existing fund interests, so money goes to work at closing rather than over years of capital calls, and the evergreen wrapper removes the drawdown notices that make closed-end private markets a hard sale to individual clients. The structure a wealth distributor can actually place tends to arrive before the strategy that shows a manager at its best.

That logic is why the deal reaches past the two firms. As this publication has argued, the wealth-channel gateway has become the scarce asset in private markets and the premium has moved from the book of assets to the seat that controls distribution. This transaction runs the arithmetic in a new direction, with the gatekeeper paying for supply: €620 million for the right to be the only wealth-channel shop selling ICG's evergreens for ten years. If the model works, expect the mirror image to follow — manufacturers tying up distribution through equity, distributors taking equity to lock product — and expect the price of exclusivity to rise with each deal signed.

The secondaries evergreen is due within weeks, and from the third quarter Amundi's reported net flows include the ICG contribution. Between the two, the €620 million will be graded long before the ten-year agreement expires.